SP Industries Acquires Bel-Art Products
News Jul 02, 2014
SP Industries, Inc. (SP) has announced that it has acquired privately held Bel-Art Products (Bel-Art). Headquartered in Wayne (NJ, USA), Bel-Art is a global provider of innovative laboratory solutions serving the scientific, industrial, and healthcare end markets.
“The acquisition of best-in-class companies that complement our existing product lines and allow us to expand our presence in the global market has proven to be a very effective strategy,” stated SP Industries CEO, Bill Downs. Downs continued by saying, “Bel-Art Products, which will continue operating under its own name, has done a superb job of building brand equity, developing a robust stream of innovative new products, and working with its channel partners to effectively serve the market. We are excited at the increased opportunities to grow market share and will cross-market across brands and leverage each organization’s expertise in product development, operations, finance, and supply chain management.”
Brad Mahood, Chief Operating Officer of Bel-Art, will play a key leadership role in sales, marketing, and product management at the corporate level. Additionally, David Landsberger, President of Bel-Art Products, will join the Board of Directors for SP Industries.
Modified Form of Botox Could Replace Opioids as Treatment for Chronic PainNews
A modified form of botulinum toxin gives long-lasting pain relief in mice without adverse effects and, in time, could replace opioid drugs as a safe and effective way of treating chronic pain, according to new research.READ MORE
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Tackling Cancer at Ground Zero: Designer Molecule Inhibits Protein TargetNews
A new molecule designed by University of Adelaide researchers shows great promise for future treatment of many cancers. The new molecule successfully targets a protein that plays a major role in the growth of most cancers.READ MORE
5th edition of the International Conference Clinical Oncology and Molecular Diagnostics
Jun 17 - Jun 18, 2019